ArticleEJHaem2025
Warm Autoimmune Haemolytic Anaemia Management in Asia-Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the burden of warm autoimmune haemolytic anaemia (wAIHA) and treatment practices in the Asia-Pacific (APAC) region. Methods: A systematic literature review (SLR) of observational studies in adult patients with wAIHA was conducted. Based on these findings, a Delphi panel was convened to develop consensus recommendations on diagnosis, treatment goals and algorithms by subtypes, unmet needs and research priorities. Results: The SLR included 37 publications. Clinical guidelines consistently recommend direct antiglobulin testing for diagnosis and corticosteroids as first-line treatment. Real-world data showed corticosteroid use in over 80% of patients, with response rates of 81%-96%, and relapse rates of 18%-45%. The Delphi panel recommended routine screening for underlying conditions and early therapeutic interventions. Key challenges identified included restricted access to rituximab in parts of the APAC region and gaps in physician awareness. Research priorities included optimising therapy, assessing long-term outcomes and improving disease awareness. Conclusion: This research emphasises the need for evidence-based, regionally adaptable treatment algorithms for wAIHA in the APAC region. Ongoing data gaps related to epidemiology, outcomes and quality of life must be addressed to enhance patient care. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.